PBLS Latest Headlines

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Bristol-Myers Squibb (BMY) and Parabilis Medicines, Inc. (PBLS)

at www.tipranks.com (Mon, 26-Oct 10:50 AM)

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Parabilis Medicines, Inc. (PBLS) and Kyverna Therapeutics, Inc. (KYTX)

at www.tipranks.com (Mon, 26-Oct 6:50 AM)

PBLS: Buy Rating Reiterated as Zolucatetide’s Best-in-Class Potential and Clear Path to Approval Support Unchanged $45 Price Target

at www.tipranks.com (Mon, 26-Oct 6:37 AM)

PBLS jumps as Parabilis tees up updated zolucatetide data for ESMO 2026—with a June 22 cutoff and a Phase 3 dosing aim

Market Chameleon (Mon, 19-Oct 11:34 AM)

PBLS Sets an October 24 Stage for Updated Zolucatetide Data in Desmoid Tumors at ESMO 2026

Market Chameleon (Mon, 19-Oct 7:11 AM)